| ²é¿´: 644 | »Ø¸´: 1 | |||
wqssfj1Ìú¸Ëľ³æ (ÖøÃûдÊÖ)
|
[ÇóÖú]
ÇóÖú·Òë-Ò©Æ·×¢²á×ÊÁÏÏà¹ØÄÚÈÝ
|
|
On day 0, following a 4-week baseline phase, patients meeting the inclusion/exclusion criteria were assigned in a blinded fashion to the study treatment in the strata of medication overuse (yes/no), as determined by the frequency of use of acute headache pain medications during the baseline phase. Within each stratum within each investigator site, patients were randomly allocated to receive either BOTOX or placebo at a 1:1 ratio within blocks of 4. ´ËΪÁÙ´²×ÊÁϸÅÒª²¿·ÖÄÚÈÝ ¶àлÁË£¡ [ Last edited by wqssfj1 on 2012-9-25 at 09:22 ] |
» ÊÕ¼±¾ÌûµÄÌÔÌûר¼ÍƼö
¾«Æ··Ò뼯½õ |
» ²ÂÄãϲ»¶
297£¬¹¤¿Æµ÷¼Á?
ÒѾÓÐ10È˻ظ´
¿ÒÇëÓÐѧУÊÕÁô
ÒѾÓÐ5È˻ظ´
322Çóµ÷¼Á
ÒѾÓÐ14È˻ظ´
294Çóµ÷¼Á
ÒѾÓÐ8È˻ظ´
0854Çóµ÷¼Á
ÒѾÓÐ10È˻ظ´
Ò»Ö¾Ô¸AÇø211£¬22408 321Çóµ÷¼Á
ÒѾÓÐ7È˻ظ´
¼±Ðèµ÷¼Á
ÒѾÓÐ4È˻ظ´
300Çóµ÷¼Á
ÒѾÓÐ6È˻ظ´
291Çóµ÷¼Á
ÒѾÓÐ6È˻ظ´
ÇóÖúµ÷¼Á£¬¿çµ÷
ÒѾÓÐ20È˻ظ´
µôÏÚ±ýl
ͳæ (СÓÐÃûÆø)
- ·ÒëEPI: 3
- Ó¦Öú: 0 (Ó×¶ùÔ°)
- ½ð±Ò: 72.6
- É¢½ð: 100
- ºì»¨: 2
- Ìû×Ó: 87
- ÔÚÏß: 13.3Сʱ
- ³æºÅ: 2025477
- ×¢²á: 2012-09-24
- ÐÔ±ð: GG
- רҵ: ±íÃæ¡¢ÐÎ̬ÓëÐÎò·ÖÎö
¡¾´ð°¸¡¿Ó¦Öú»ØÌû
¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï
sltmac: ½ð±Ò-15, »úÆ÷·Ò룬ÔÙ´ÎÎ¥¹æ½«ÔÚ±¾°æ½ûÑÔ£¬Ð»Ð»ºÏ×÷£¡ 2012-11-09 23:03:48
sltmac: ½ð±Ò-15, »úÆ÷·Ò룬ÔÙ´ÎÎ¥¹æ½«ÔÚ±¾°æ½ûÑÔ£¬Ð»Ð»ºÏ×÷£¡ 2012-11-09 23:03:48
| µÚ0Ì죬ΪÆÚ4ÖܵĻùÏ߽׶κ󣬻¼ÕßµÄÄÉÈë/Åųý±ê×¼ÒÔ˫äµÄ·½Ê½·ÖÅäµÄÑо¿ÖÎÁÆ£¬¹ý¶ÈÓÃÒ©µÄ½×²ã£¨ÊÇ/·ñ£©£¬¼±ÐÔʹÓÃµÄÆµÂÊÍ·Í´µÄֹʹҩÔÚ»ùÏ߽׶Ρ£ÔÚÿ¸ö²ãÄÚÿ¸öµ÷²éµØµãÖУ¬»¼Õß±»Ëæ»ú·ÖÅä4¿é°´1:1µÄ±ÈÀýÄÚ£¬½ÓÊÜÈâ¶¾¸Ë¾ú»ò°²Î¿¼Á¡£ |

2Â¥2012-10-01 20:53:11













»Ø¸´´ËÂ¥